

### Chart for ongoing monitoring during methylphenidate (MPH) treatment

As outlined in the prescribing information in more detail, growth, psychiatric and cardiovascular status should be regularly monitored:

- Blood pressure and pulse should be recorded at each adjustment of dose and then at least every 6 months
- Height, weight and appetite should be recorded at least 6-monthly with maintenance of a growth chart
- Development of *de novo* or worsening of pre-existing psychiatric disorders should be monitored at every adjustment of dose and then at least every 6 months and at every visit

Date of initial assessment: \_\_\_\_\_ Patient name: \_\_\_\_\_

Date of birth: \_\_\_\_\_ Age: \_\_\_\_\_ Gender: \_\_\_\_\_

|                       | Baseline | Subsequent appointments |  |  |  |  |  |  |  |  |  |  |  |
|-----------------------|----------|-------------------------|--|--|--|--|--|--|--|--|--|--|--|
| Date of assessment    |          |                         |  |  |  |  |  |  |  |  |  |  |  |
| Reason for assessment |          |                         |  |  |  |  |  |  |  |  |  |  |  |
| Blood Pressure*       |          |                         |  |  |  |  |  |  |  |  |  |  |  |
| Heart rate*           |          |                         |  |  |  |  |  |  |  |  |  |  |  |
| Body weight (kg)**    |          |                         |  |  |  |  |  |  |  |  |  |  |  |
| Height (cm)**         |          |                         |  |  |  |  |  |  |  |  |  |  |  |
| Appetite**            |          |                         |  |  |  |  |  |  |  |  |  |  |  |
|                       |          |                         |  |  |  |  |  |  |  |  |  |  |  |

\*Blood pressure and heart rate should be recorded at each adjustment of dose and then at least every 6 months

\*\*Height, weight and appetite should be recorded at least 6-monthly with maintenance of a growth chart

**You can report any problem or adverse events through:**

Novartis Consulting AG.  
 Saudi Arabia: P.O. Box 16032, Riyadh 11464,  
 Phone: +996112658100  
 Fax: +966112658107  
 Email: adverse.events@novartis.com

Saudi Food and Drug Authority, National Pharmacovigilance and Drug Safety Center  
 Toll free phone: 8002490000  
 Fax: +966112057662  
 E-mail: npc.drug@sFDA.gov.sa  
 Or by online: <https://ade.sFDA.gov.sa>